^
Association details:
| Biomarker: | EGFR T854A + EGFR T790M |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durable response to osimertinib in an advanced lung adenocarcinoma patient with an uncommon EGFR T854A mutation: A case report
Published date:
12/09/2022
Excerpt:
The patient was diagnosed with stage IVA lung adenocarcinoma with an exceptionally uncommon EGFR T854A mutation in exon 21 was detected concomitantly with EGFR T790M in blood by next-generation sequencing (NGS)….Our patient exhibited a partial response (PR) to osimertinib with progression-free survival of nearly 8 months.
DOI:
10.1097/MD.0000000000031875
